Table 1. Characteristics of Patients With Early Breast Cancer From 2 Databasesa.
| Characteristic | Database | |
|---|---|---|
| CSCO BC (n = 45 970) | Flatiron Health (n = 11 750) | |
| Age, median (IQR), y | 47 (40-56) | 64 (54-73) |
| Diagnosis time | ||
| 2011-2016 | 33 427 (72.7) | 5684 (48.4) |
| 2017-2021 | 12 543 (27.3) | 6066 (51.6) |
| Menstrual status | ||
| Premenopausal | 24 226 (52.7) | 2077 (19.7) |
| Postmenopausal | 21 744 (47.3) | 8492 (80.3) |
| Clinical stage | ||
| I | 7250 (31.8) | 2409 (54.6) |
| II | 10 043 (44.1) | 1481 (33.6) |
| III | 5501 (24.1) | 523 (11.9) |
| Phenotypes | ||
| HR positive–ERBB2 negative | 15 079 (53.9) | 8708 (75.5) |
| HR positive–ERBB2 positive | 4439 (15.9) | 1383 (12.0) |
| HR negative–ERBB2 positive | 4007 (14.3) | 416 (3.6) |
| TNBC | 4439 (15.9) | 1025 (8.9) |
| Neoadjuvant therapy | 10 642 (23.1) | 1804 (15.4) |
| Surgery | 41 511 (90.3) | 11 316 (96.3) |
| Adjuvant therapy | 27 122 (59.0) | 8664 (73.7) |
Abbreviation: CSCO BC, Chinese Society of Clinical Oncology Breast Cancer; ERBB2, formerly HER2 or HER2/neu; HR, hormone receptor; TNBC, triple-negative breast cancer.
a
Unless otherwise indicated, data are expressed as No. (%) of patients. Patients with missing data were excluded when calculating the proportions.